Marisa, MD, Internal medicine, is currently Honorary Professor at Imperial College London, Lecturer in pharmacogenomics at the University of Tor Vergata Rome, and member of the Editorial Board of Precision NanoMedicine Journal.
Former European Medicines Agency Senior Scientific Advisor, Marisa is expert in pharmaceuticals regulatory science with established professional track record in strategies for advanced and innovative health products pipelines. Liaison with regulators, sponsors, clinicians, patients and public health professionals, constitutes important elements of Marisa’s professional asset.
Experienced Medtech executive with track record of successfully leading multifunctional teams to develop prototype device towards clinic ready product.
Specialised in identifying and progressing innovative healthcare assets towards commercialisation.
Ian Bruce is Professor of Rheumatology and Vice Dean for Health and Care Partnerships, Faculty of Biology, Medicine and Health, the University of Manchester. He is Director of the National Institute of Health Research (NIHR) Manchester Biomedical Research Centre (BRC). ). Manchester BRC seeks to address the major causes of health inequity across our diverse urban, rural and coastal settings by providing infrastructure to support early translational research in Greater Manchester, Lancashire and South Cumbria with a focus on delivering ‘personalised health and care for all’. It is the largest BRC outside the Greater South-East.
Professor Bruce qualified in medicine from Queen’s University Belfast in 1988 and gained his MRCP in 1991. He trained in medicine and rheumatology in Northern Ireland and completed his MD thesis on the pathogenesis of systemic vasculitis in 1995. He was the Geoff Carr Lupus Fellow at the University of Toronto with Murray Urowitz and Dafna Gladman (1996-98) before moving to Manchester in 1998.
He is former Chair of the Systemic Lupus International Collaborating Clinics (SLICC) group and a member of the British Isles Lupus Assessment Group (BILAG). He leads the BILAG Biologics Register for SLE and is Chief Investigator on the SLICC/LFA/ACR Damage Index Renewal Project. He is Chair of the Astra Zeneca Anifrolumab in SLE Global Steering Group.
Professor Bruce’s research is focused on the association between inflammatory rheumatic diseases and premature atherosclerosis/coronary heart disease as well as personalised medicine in SLE.
Nina Skorytchenko is a biotech and business leader with over a decade of experience bridging science and commerce across precision medicine, diagnostics, and digital health. She is the Co-Founder and CEO of Avenna Ltd, a UK-based company developing GlyHealth, a glycomics-based biomarker platform for chronic inflammatory diseases.
Her work focuses on translating complex R&D into scalable clinical and market applications, bringing together biotech innovators, clinicians, and industry partners across the UK, EU, and Spain. Nina has led multiple international collaborations in precision diagnostics, real-world data integration, and multi-omics research, including the ProVision-RA project — a cross-disciplinary initiative aimed at integrating glycomics, proteomics, and clinical data to improve disease-stratification and treatment-response prediction in rheumatoid arthritis.
With a foundation in finance and strategic partnerships (Nomura International, Bloomberg LP, Vestra Wealth), she combines scientific understanding with commercial acumen to accelerate the adoption of data-driven healthcare and AI-enabled biomarker discovery.
Having recently relocated to Valencia, Spain, Nina continues to build bridges between European biotech ecosystems and global markets, promoting collaboration at the intersection of multi-omics, clinical data management, and precision medicine innovation.
Dr Martin Edobor is an NHS GP and Clinical Lead for Digital transformation at North East London ICB. He is the former clinical director for North Newham Primary Care Network and former Chair of the Fabian Society
Angela has been working for the biopharmaceutical Industry for the past 19 years in various roles including clinical development , post marketing research , business operations and real world evidence . She held senior position in Real World Evidence generation at both Sanofi and Bayer and has recently joined EMMEs as head of Real World Evidence. Prior to embarking on a career in the pharmaceutical Industry Angela worked as an Epidemiologist at the LMU Institut of Epidemiology in Munich. Angela holds a Doctorate degree in Environmental Epidemiology as well as a Masters Degrees in Public Health , Nutrition and Business Administration.
Innovation-driven clinician and an enterpreneurial enthusiast based at the Manchester Academy of Health Sciences Centre, Manchester University Hospitals. Recognised as an influential health technology leader with major contributions to innovation in healthcare technology, dialysis and delivery systems.
Passionate about transforming clinical services and patient pathways through enabling technology.
In various leadership roles as Deputy Director of NIHR MedTech Cooperative Devices for Dignity, Vice Chair for EUDIAL, ERA-EDTA, Chair of the Haemodialysis Study group for UK Kidney Research Consortium. Driving safe and value based health care with national organisations as CQC Speciality Advisor, and as Clinical Reference Group Member for NHS England.
Managing a diverse portofolio of translational clinical academic research with a global network of collaborators. A trainer, educator and mentor for health professionals at the University of Manchester. Several publications, patents, authored book chapters and media reports of the work in the field.
Experienced Board level Director and leader within the health and care sector. A values driven leader centred around people, continually striving for innovation and improvements that enhance patient, colleague and customer experience.
My career demonstrates senior positions in the portfolios of organisational development, culture, operational management and delivery, consultancy and quality and improvement transformation roles.
I have purposely gained experience both in the public and private sector, thus operating business and population based leadership and delivery. I am therefore experienced in both commercial and public facing businesses.
Global General Counsel and member of the Amryt Group Executive Leadership Team.
Qualified lawyer in the US (New York), England and Wales and Ireland with experience in Corporate M&A, Tech, Media and Telecoms, Life Sciences and Commercial Contract matters. A proven contract negotiator in the M&A space, with experience in contract drafting and identifying client needs.
Responsible for advising the Amryt Group on M&A, commercial contracts, licensing, data protection, general corporate matters, managing external counsel, global legal budgets and ensuring external legal resources are aligned globally for the Amryt Group.
John was identified and recognised as one of the most influential and innovative General Counsels in the Legal 500 (Legalease) GC Powerlist: Ireland 2022 and GC Powerlist: Ireland Teams 2023. Won Life Sciences Lawyer of the Year at the Irish legal awards and nominated at the Irish Law Awards for Lawyer of the Year; Life Sciences Lawyer of the Year; and In-House Lawyer of the Year 2022.
